Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22482286 | 0.86 | ADORA1 (0.37) | ADORA1GRAMD1APRKCISCN9AESR2 | |
| SCHEMBL22481978 | 0.80 | HSP90AA1 (0.45) | HDAC1HDAC6MAPT | |
| SCHEMBL22482006 | 0.80 | RBP4 (0.41) | GSK3BDYRK1A | |
| SCHEMBL22482233 | 0.79 | ADORA1 (0.52) | ADORA1GRAMD1ASCN9AESR2MKNK1 | |
| SCHEMBL22482028 | 0.77 | ADORA1 (0.56) | ADORA1ESR2KDM4EMAPTNR1H2 | |
| SCHEMBL10413878 | 0.74 | ADORA1 (0.48) | ADORA1GRAMD1ASCN9AESR2MKNK1 | |
| SCHEMBL22482123 | 0.72 | GSK3B (0.38) | GSK3BDYRK1A | |
| SCHEMBL22482231 | 0.71 | ADORA1 (0.45) | ADORA1ESR2MKNK1KDM4EMAPT | |
| SCHEMBL22482203 | 0.66 | CDK5 (0.44) | KDM4E | |
| SCHEMBL6424372 | 0.65 | ADORA1 (0.53) | ADORA1GRAMD1AESR2MKNK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2022-04-21 | — | — | US | disclosed |
| WO-2020198583-A1 | BICYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | ADORA1 3877/4885GRAMD1A 3949/4885ACKR3 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.